ESCRS Homepage

July 2003
IN THIS ISSUE
Ocular symptoms often the first sign of CMV-R in HIV- infected patients

When measuring quality of vision - scatter matters

Symposium to highlight ‘The next generation of IOLs'


Anti-HIV Drugs Save Vision of AIDS Patients


HIV is a risk factor for corneal ulceration


HIV-infection implicated in ischaemic maculopathy


Unexpected visual sensations may alarm surgical patients undergoing peribulbar anaesthesia


OHTS study shows that risk factor profiling can aid in treatment decisions for ocular hypertensives


Hi- tech centres boost care for glaucoma patients


OCT reliable, accurate technique for corneal thickness measurement


French survey shows changing practice patterns


Pre-op pupillometry reduces post-op unhappiness


French ophthalmology at a turning point?


US cataract surgeons change with the times


US LASIK market static but outlook good


Prosperity around the corner?


Russian mobile ophthalmic surgery unit brings relief to dispersed elderly population


Industry Briefs


Virtual reality lab boosts hi-tech vision research


Patients forget about two-thirds of doctors' treatment instructions, says neuropsychologist


Outlook on industry: Spin-off brings the best of both worlds


Incidence of wavefront aberrations varies widely in healthy eyes


FEATURES
From The Editor

Reflections on Refractive Surgery

Bio-Ophthalmology. From foe to friend: using HIV to treat genetic eye disease


Regulatory Matters. LASIK malpractice lawsuits establish European beachhead


Journal Watch. Vision science highlights from the world's leading journals of medicine and science


Intraocular antiseptic doubles as medium for Seidel testing


In your good books

 


Prosperity around the corner?

Some three million people in US have had refractive surgery. Another 35 million wear contact lenses, while 140 million wear glasses. These statistics alone are enough to encourage, Gilbert Kliman MD to be optimistic about the prospects for refractive surgery in the near future. "We’re in a huge market that is still minimally penetrated. Only a small number of patients have been treated, and a lot more out there will be. There are many innovative technologies coming into play now that will broaden the spectrum of patients that can be treated, giving them better visual outcomes."

Dr Kliman enumerated several major factors that would affect refractive surgery volume. First, technologic innovations are giving better visual outcomes. A majority of patients now achieve 20/20, and incremental improvements provided by new technologies such as wavefront sensing and femtosecond lasers may make this procedure even better. "We now have more surgical options than ever before. Perhaps the main challenge is choosing between these to determine which will produce best results for our patients." In this regard, Dr Kliman advised surgeons to focus on building their practices by talking to patients and recommending specific procedures.

He recommended focusing on the patient’s experience, doing whatever can be done to improve outcomes. "There have been some unsuccessful experiments with direct to consumer advertising or using optometrist networks to drive volume. These really have not worked. We need to talk about the value to the patient, not just the price. Cutting prices has not grown the market and may have even decreased the dollar size of the market. Price cutting is a self inflicted would by ophthalmologists that is completely preventable."

He cited consumer perception as another very important aspect of the current situation. While market surveys suggest that LASIK is generally perceived well, it is clear that the public is concerned about the potential complications of refractive surgery. The remedy for this is for surgeons to continue to work to reduce complication and reoperation rates. The factor influencing the refractive market that is most discussed is also the one over which surgeons have the least influence- the economy. LASIK volume decreased in tandem with the general economy. At the same time surgeons are facing increasing costs as new technologies become available.

Current market conditions notwithstanding, Dr Kliman predicted a recovery in the refractive market in the next couple of years. "Perhaps the time to start investing for that recovery is right now. When the excimer laser was introduced in 1995 the procedure cost was $250 per eye and many questioned whether there was even a market for laser vision correction. The people who invested in 1995 and 1996 went on to become the high volume surgeons during the boom."

Gilbert Kliman MD
Menlo Park
CA 94025 USA
Gkliman@interwest.com